1) Sylvester RJ, van der Meijden APM, Oosterlinck W, et al : Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables : a combined analysis of 2596 patients from seven EORTC trials. Eur Urol 49 : 466─477, 2006
2) 日本泌尿器科学会(編) : 膀胱癌診療ガイドライン 2015年版. 医学図書出版社, 東京, 2015
3) Babjuk M, Burger M, Zigeuner R, et al : EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder : update 2013. Eur Urol 64 : 639─653, 2013
4) Hall MC, Chang SS, Dalbagni G, et al : Guideline for the management of nonmuscle invasive bladder cancer(stages Ta, T1, and Tis): 2007 update. J Urol 178 : 2314─2330, 2007
5) Nieder AM, Brausi M, Lamm D, et al : Management of stage T1 tumors of the bladder : International Consensus Panel. Urol 66 : 108─125, 2005
6) Sylvester RJ, van der Meijden A, Witjes JA, et al : High-grade Ta urothelial carcinoma and carcinoma in situ of the bladder. Urol 66 : 90─107, 2005
7) Brausi M, Witjes JA, Lamm D, et al : A review of current guidelines and best practice recommendations for the management of nonmuscle invasive bladder cancer by the International Bladder Cancer Group. J Urol 186 : 2158─2167, 2011
8) Babjuk M, Oosterlinck W, Sylvester R, et al : EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder. Eur Urol 54 : 303─314, 2008
9) Fernadez-Gomez J, Madero R, Solsosa E, et al : Predicting non-muscle invasive bladder cancer recurrence and progression in patients treated with bacillus Calmette-Guérin : the CUETO scoring model. J Urol 182 : 2195─2203, 2009
10) Kitamura H and Kakehi Y : Treatment and management of high-grade T1 bladder cancer : what should we do after second TUR? Jpn J Clin Oncol 45 : 315─322, 2015
11) Shirakawa H, Kikuchi E, Tanaka N, et al : Prognostic significance of bacillus Calmette-Guérin failure classification in non-muscle-invasive bladder cancer. BJU Int 110 : E216─221, 2012
12) Nishiyama N, Kitamura H, Hotta H, et al : Construction of predictive models for cancer-specific survival of patients with non-muscle-invasive bladder cancer treated with bacillus Calmette-Guérin : results from a multicenter retrospective study. Jpn J Clin Oncol 44 : 1101─1108, 2014
13) Herr HW and Sogani PC : Does early cystectomy improve the survival of patients with high risk superficial bladder tumors? J Urol 166 : 1296─1299, 2001
14) Denzinger S, Fritsche HM, Otto W, et al : Early versus deferred cystectomy for initial high-risk pT1G3 urothelial carcinoma of the bladder : do risk factors define feasibility of bladder-sparing approach? Eur Urol 53 : 146─152, 2008
15) Hautmann RE, Volkmer BG and Gust K : Quantification of the survival benefit of early versus deferred cystectomy in high-risk non-muscle invasive bladder cancer(T1 G3). World J Urol 27 : 347─351, 2009
16) Jäger W, Thomas C, Haag S, et al : Early vs delayed radical cystectomy for ‘high-risk’ carcinoma not invading bladder muscle : delay of cystectomy reduces cancer-specific survival. BJU Int 108 : E284─288, 2011
17) Badalato GM, Gaya JM, Hruby G, et al : Immediate radical cystectomy vs conservative management for high grade cT1 bladder cancer : is there a survival difference? BJU Int 110 : 1471─1477, 2012
18) Dalbagni G, Vora K, Kaag M, et al : Clinical outcome in a contemporary series of restaged patients with clinical T1 bladder cancer. Eur Urol 56 : 903─910, 2009
19) Sternberg IA, Keren Paz GE, Chen LY, et al : Role of immediate radical cystectomy in the treatment of patients with residual T1 bladder cancer on restaging transurethral resection. BJU Int 112 : 54─59, 2013
20) Segal R, Yafi FA, Brimo F, et al : Prognostic factors and outcome in patients with T1 high-grade bladder cancer : can we identify patients for early cystectomy? BJU Int 109 : 1026─1030, 2012